In this episode, we look to the future of Sjogren’s care—one that’s more personalized, precise, and full of hope. We talk through how the condition is managed today and map out the key patient phenotypes, as well as explore breakthrough treatments now in late-stage trials, explaining how the next five years could transform how we treat this complex disease.

About Dr. Nancy Carteron

Dr. Carteron is a Professor at the University of California, Berkeley, and the immediate past chair of the Medical and Scientific Advisory group of the Sjogren’s Foundation. She currently sees patients at the Interdisciplinary Sjogren’s Clinic at UC Berkeley. She is a nationally recognized leader in clinical innovation and research for Sjögren’s disease.

In this episode, we explore:

(00:00) Patient-centric Sjogren's diagnosis strategy

(05:21) Lymphoproliferative risks in Sjogren's

(08:49) Sjogren's: fatigue, brain fog, inflammation

(10:45) Late-stage clinical trials with therapies designed specifically for Sjogren’s

(11:50) Targeting pathways in autoimmunity

(14:28) Undetected antibodies in Sjogren's disease

(17:51) If you take one thing from this episode...

Learn more about your ad choices. Visit podcastchoices.com/adchoices